GSK plc:
* GSK PLC - GSK AND CUREVAC COLLABORATION RESTRUCTURED
* GSK PLC - GSK AND CUREVAC COLLABORATION RESTRUCTURED
* GSK PLC - ACQUIRES FULL RIGHTS TO DEVELOP VACCINES
* GSK - CUREVAC RECEIVES EUR 400 MILLION UPFRONT AND UP TO AN ADDITIONAL EUR 1.05 BILLION
* GSK - GSK WILL ASSUME FULL CONTROL OF DEVELOPING AND MANUFACTURING CANDIDATE VACCINES
* GSK - ADDITIONAL EUR 1.05 BILLION IN DEVELOPMENT, REGULATORY AND SALES MILESTONES AND TIERED ROYALTIES IN HIGH SINGLE TO LOW TEENS RANGE Source text for Eikon: Further company coverage: